1: Clarke R, Derry S, Moore RA. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2014 May 8;5:CD004309. doi: 10.1002/14651858.CD004309.pub4. Review. PubMed PMID: 24809657.
2: Lories RJ. Etoricoxib and the treatment of ankylosing spondylitis. Expert Opin Drug Metab Toxicol. 2012 Dec;8(12):1599-608. doi: 10.1517/17425255.2012.741120. Epub 2012 Nov 6. Review. PubMed PMID: 23126318.
3: Clarke R, Derry S, Moore RA. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2012 Apr 18;4:CD004309. doi: 10.1002/14651858.CD004309.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;5:CD004309. PubMed PMID: 22513922.
4: Alekseeva LI. [Comparative evaluation of the safety and efficacy of etoricoxib and diclofenac on the upper gastrointestinal tract in patients with osteoarthrosis and rheumatoid arthritis (the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program)]. Ter Arkh. 2010;82(8):57-62. Review. Russian. PubMed PMID: 20873248.
5: Croom KF, Siddiqui MA. Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis. Drugs. 2009 Jul 30;69(11):1513-32. doi: 10.2165/00003495-200969110-00008. Review. PubMed PMID: 19634927.
6: Clarke R, Derry S, Moore RA, McQuay HJ. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD004309. doi: 10.1002/14651858.CD004309.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD004309. PubMed PMID: 19370600.
7: Chilet-Rosell E, Ruiz-Cantero MT, Horga JF. Women's health and gender-based clinical trials on etoricoxib: methodological gender bias. J Public Health (Oxf). 2009 Sep;31(3):434-45. doi: 10.1093/pubmed/fdp024. Epub 2009 Mar 14. Review. PubMed PMID: 19287020.
8: Takemoto JK, Reynolds JK, Remsberg CM, Vega-Villa KR, Davies NM. Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. Clin Pharmacokinet. 2008;47(11):703-20. Review. PubMed PMID: 18840026.
9: Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008 Apr;12(11):1-278, iii. Review. PubMed PMID: 18405470.
10: Yuan Y, Hunt RH. Global gastrointestinal safety profile of etoricoxib and lumiracoxib. Curr Pharm Des. 2007;13(22):2237-47. Review. PubMed PMID: 17691997.
11: Capone ML, Tacconelli S, Patrignani P. Clinical pharmacology of etoricoxib. Expert Opin Drug Metab Toxicol. 2005 Aug;1(2):269-82. Review. PubMed PMID: 16922642.
12: Aldington S, Shirtcliffe P, Weatherall M, Beasley R. Systematic review and meta-analysis of the risk of major cardiovascular events with etoricoxib therapy. N Z Med J. 2005 Oct 7;118(1223):U1684. Review. PubMed PMID: 16224508.
13: Martina SD, Vesta KS, Ripley TL. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother. 2005 May;39(5):854-62. Epub 2005 Apr 12. Review. PubMed PMID: 15827069.
14: Matsumoto AK, Cavanaugh PF Jr. Etoricoxib. Drugs Today (Barc). 2004 May;40(5):395-414. Review. PubMed PMID: 15319795.
15: Leclercq P, Malaise MG. [Etoricoxib (Arcoxia)]. Rev Med Liege. 2004 May;59(5):345-9. Review. French. PubMed PMID: 15270001.
16: Patrignani P, Capone ML, Tacconelli S. Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. Expert Opin Pharmacother. 2003 Feb;4(2):265-84. Review. PubMed PMID: 12562317.
17: Cochrane DJ, Jarvis B, Keating GM. Etoricoxib. Drugs. 2002;62(18):2637-51; discussion 2652-3. Review. PubMed PMID: 12466002.

Chemical
CAS Num	202409-33-4
Chemical Formula	C18H15ClN2O2S
Molecular Weight	358.8419
IUPAC Chemical Name	5-Chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine
Exact Mass	358.0543
Elemental Analysis	C, 60.25; H, 4.21; Cl, 9.88; N, 7.81; O, 8.92; S, 8.94
Synonym	Etoricoxib, Arcoxia, L-791456, MK 0663, MK-0663
Solubility	Soluble in DMSO, not in water
SMILES Code	O=S(C1=CC=C(C2=CC(Cl)=CN=C2C3=CC=C(C)N=C3)C=C1)(C)=O
Biological
Targets and Effects	COX-2 inhibitor
Pathways	Apoptosis
Physical
Appearance	Solid powder
Purity	>98% (or refer to the Certificate of Analysis)
Shipping Condition	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition	Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Shelf Life	>2 years if stored properly